Prognostic Impact of PD-1 and Tim-3 Expression in Tumor Tissue in Stage I-III Colorectal Cancer.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
10
2019
revised:
26
03
2020
accepted:
15
04
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
26
3
2021
Statut:
epublish
Résumé
Programmed cell death receptor 1 (PD-1) and T cell immunoglobulin mucin-3 (Tim-3) are considered as important immunosuppressive molecules and play an important role in tumor immune escape and cancer progression. However, it remains unclear whether PD-1 and Tim-3 are coexpressed in stage I-III colorectal cancer (CRC) and how they impact on the prognosis of the disease. A total of two cohorts with 451 patients who underwent surgery for stage I-III CRC treatment were enrolled in the study. Among which, 378 cases were from The Cancer Genome Atlas (TCGA) database and 73 cases were from the Fourth Hospital of Hebei Medical University (FHHMU) cohort. The mRNA expressions of PD-1 and Tim-3 in tumor tissue in stage I-III CRC were obtained from TCGA database. Immunohistochemistry was used to assess the expressions of PD-1 and Tim-3 in tumor tissue in stage I-III CRC in the FHHMU cohort. Interactive relationships between PD-1 and Tim-3 were retrieved through the online STRING database, which was used to study the interactions between proteins. DAVID, consisting of comprehensive biological function annotation information, was applied for the GO and KEGG pathway enrichment analysis of the interactive genes. In the FHHMU cohort, the high expressions of PD-1 and Tim-3 were, respectively, found in 42.47% and 84.93% of stage I-III CRC tissue. PD-1 was significantly associated with age, primary site, and lymphatic metastasis. Tim-3 was closely related to the primary site. Correlation analysis showed that PD-1 and Tim-3 were positively correlated ( In summary, upregulation of PD-1 and Tim-3 in stage I-III CRC tumor tissue could be associated with the poor prognosis of patients. Those patients with coexpression of PD-1 and Tim-3 may have a significantly worse prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Programmed cell death receptor 1 (PD-1) and T cell immunoglobulin mucin-3 (Tim-3) are considered as important immunosuppressive molecules and play an important role in tumor immune escape and cancer progression. However, it remains unclear whether PD-1 and Tim-3 are coexpressed in stage I-III colorectal cancer (CRC) and how they impact on the prognosis of the disease.
MATERIALS AND METHODS
METHODS
A total of two cohorts with 451 patients who underwent surgery for stage I-III CRC treatment were enrolled in the study. Among which, 378 cases were from The Cancer Genome Atlas (TCGA) database and 73 cases were from the Fourth Hospital of Hebei Medical University (FHHMU) cohort. The mRNA expressions of PD-1 and Tim-3 in tumor tissue in stage I-III CRC were obtained from TCGA database. Immunohistochemistry was used to assess the expressions of PD-1 and Tim-3 in tumor tissue in stage I-III CRC in the FHHMU cohort. Interactive relationships between PD-1 and Tim-3 were retrieved through the online STRING database, which was used to study the interactions between proteins. DAVID, consisting of comprehensive biological function annotation information, was applied for the GO and KEGG pathway enrichment analysis of the interactive genes.
RESULTS
RESULTS
In the FHHMU cohort, the high expressions of PD-1 and Tim-3 were, respectively, found in 42.47% and 84.93% of stage I-III CRC tissue. PD-1 was significantly associated with age, primary site, and lymphatic metastasis. Tim-3 was closely related to the primary site. Correlation analysis showed that PD-1 and Tim-3 were positively correlated (
CONCLUSION
CONCLUSIONS
In summary, upregulation of PD-1 and Tim-3 in stage I-III CRC tumor tissue could be associated with the poor prognosis of patients. Those patients with coexpression of PD-1 and Tim-3 may have a significantly worse prognosis.
Identifiants
pubmed: 32509862
doi: 10.1155/2020/5294043
pmc: PMC7244975
doi:
Substances chimiques
HAVCR2 protein, human
0
Hepatitis A Virus Cellular Receptor 2
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5294043Informations de copyright
Copyright © 2020 Wentao Kuai et al.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest.
Références
Mol Med Rep. 2017 Feb;15(2):689-695
pubmed: 28035413
Chin Med Sci J. 2018 Sep 20;33(3):174-182
pubmed: 30266108
J Surg Oncol. 2018 Jun;117(7):1405-1412
pubmed: 29663398
Oncogene. 2018 May;37(18):2456-2468
pubmed: 29449693
J Immunol. 2018 May 1;200(9):3291-3303
pubmed: 29581358
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Sci Rep. 2019 Jul 10;9(1):10004
pubmed: 31292525
Onco Targets Ther. 2019 May 14;12:3671-3682
pubmed: 31190869
Cell Oncol (Dordr). 2016 Oct;39(5):397-410
pubmed: 27126599
Int Immunol. 2018 Sep 25;30(10):445-454
pubmed: 29939325
Oncol Lett. 2018 Jul;16(1):1059-1066
pubmed: 29963183
Front Pharmacol. 2019 Feb 28;10:139
pubmed: 30873025
BMC Cancer. 2019 Apr 16;19(1):360
pubmed: 30992011
Hepatology. 2012 Oct;56(4):1342-51
pubmed: 22505239
World J Surg. 2012 Feb;36(2):424-30
pubmed: 22187130
Trends Immunol. 2011 Aug;32(8):345-9
pubmed: 21697013
Oncoimmunology. 2018 Jun 11;7(8):e1465165
pubmed: 30221062
Cell Mol Immunol. 2010 Sep;7(5):389-95
pubmed: 20514052
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Biomed Pharmacother. 2019 Feb;110:312-318
pubmed: 30522017
Trends Immunol. 2001 May;22(5):265-8
pubmed: 11323285
Immunology. 2019 Sep;158(1):35-46
pubmed: 31429085
Cell Prolif. 2019 May;52(3):e12571
pubmed: 30714229
J Exp Med. 2010 Mar 15;207(3):505-20
pubmed: 20176801
J Exp Med. 2000 Oct 2;192(7):1027-34
pubmed: 11015443
Int J Clin Exp Pathol. 2015 Jul 01;8(7):8018-27
pubmed: 26339368
Mod Pathol. 2016 Nov;29(11):1433-1442
pubmed: 27443512
Mutat Res. 2019 Apr - Jun;780:69-81
pubmed: 31395351
J BUON. 2019 May-Jun;24(3):883-888
pubmed: 31424637
Clin Cancer Res. 2019 Aug 1;25(15):4820-4831
pubmed: 31076549
BMC Cancer. 2009 Dec 26;9:463
pubmed: 20035626
Cancer Cell. 2016 Dec 12;30(6):925-939
pubmed: 27866850
J Clin Invest. 2019 Oct 1;129(10):4464-4476
pubmed: 31524634
Br J Surg. 2019 Sep;106(10):1352-1361
pubmed: 31414718
J Immunother Cancer. 2015 May 19;3:21
pubmed: 25992292
J Exp Med. 2010 Sep 27;207(10):2175-86
pubmed: 20819923
Oncol Rep. 2016 Sep;36(3):1551-61
pubmed: 27430162
J Gastrointest Oncol. 2018 Feb;9(1):170-179
pubmed: 29564183
World J Surg. 2002 Jan;26(1):59-66
pubmed: 11898035
Int J Clin Exp Med. 2015 May 15;8(5):7029-38
pubmed: 26221240
Cancer Res. 2014 Feb 15;74(4):1045-55
pubmed: 24343228
J Zhejiang Univ Sci B. 2019 Jul 12;:
pubmed: 31317681
Curr Top Microbiol Immunol. 2017;410:127-156
pubmed: 28900677
Clin Cancer Res. 2017 Aug 1;23(15):4416-4428
pubmed: 28213366
Cancer Res. 2013 Jan 1;73(1):128-38
pubmed: 23135914
Int Immunopharmacol. 2017 Feb;43:210-218
pubmed: 28038383
Oncoimmunology. 2017 Aug 18;6(9):e1331194
pubmed: 28932634
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Immunol Res. 2019 Mar 31;2019:8505021
pubmed: 31049361
PLoS One. 2012;7(2):e30852
pubmed: 22347406
Exp Cell Res. 2013 Jul 1;319(11):1611-7
pubmed: 23499738
J Exp Med. 2017 Apr 3;214(4):895-904
pubmed: 28302645
Medicine (Baltimore). 2015 Feb;94(6):e515
pubmed: 25674748